Terns Pharmaceuticals Inc Stock News

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr. his pick to head the Department of Health and Human Services.

FOSTER CITY, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of October 1, 2024 an equity inducement award to a new employee unde...

Terns Pharmaceuticals is developing TERN-601, an oral GLP-1R agonist, which showed a placebo-adjusted weight loss of 4.9% in a phase 1 trial for obesity treatment. The company plans to initiate a phase 2 study for TERN-601 in 2025, creating a significant catalyst opportunity for investors. The company is also developing TERN-701 for chronic myeloid leukemia, with interim phase 1 data expected i...

Terns Pharmaceuticals recently posted positive results from a clinical trial involving a weight-loss pill. The results looked better than those from a key rival.

Viking Therapeutics isn't the only weight loss biotech out there. Terns Pharmaceuticals just published some good phase 1 clinical trial data.

Terns Pharmaceuticals' early-stage weight loss asset just reported positive clinical trial results. Even though it's showing some promise, Terns remains a risky bet.

Terns Pharmaceuticals just reported some strong data from a phase 1 clinical trial. The data suggest that it might be able to make a highly tolerable weight loss drug.

The 'Undercovered' Dozen series highlights 12 undercovered stocks, providing investment ideas and sparking community discussion on their potential. Zach Bristow argues that Sylvamo Corporation offers a compelling risk/reward opportunity with reasonable valuations, shareholder-oriented management, and potential valuations up to $200/share. NuScale Power Corporation faces skepticism, according to...